Cellular implant therapy - Takeda
Latest Information Update: 07 Sep 2021
At a glance
- Originator ARIAD Pharmaceuticals
- Class Antihyperglycaemics; Mesenchymal stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Myocardial infarction
Most Recent Events
- 16 Feb 2017 ARIAD Pharmaceuticals has been acquired by Takeda
- 20 Aug 2003 Discontinued - Preclinical for Myocardial infarction in USA (unspecified route)
- 10 Feb 2003 No development reported - Preclinical for Myocardial infarction in USA (unspecified route)